Buscar en
Farmacia Hospitalaria (English Edition)
Toda la web
Inicio Farmacia Hospitalaria (English Edition) Effectiveness and safety of erlotinib in 2 patients with carcinoma of the cervix
Journal Information
Vol. 33. Issue 2.
Pages 96-99 (January 2009)
Download PDF
More article options
Vol. 33. Issue 2.
Pages 96-99 (January 2009)
Full text access
Effectiveness and safety of erlotinib in 2 patients with carcinoma of the cervix
Efectividad y seguridad de erlotinib en 2 pacientes con carcinoma de cérvix uterino
I. Pérez Rodrigoa,
Corresponding author

Corresponding author.
, R. Albornoz Lópeza, M. Soto Rojasb, I. Fernández Garcíaa, V. Torres Degayóna
a Servicio de Farmacia, Hospital Reina Sofía, Córdoba, Spain
b Servicio de Farmacia, Hospital San Juan de Dios, San José, Costa Rica
Article information
Download PDF

To assess the effectiveness and safety of the use of erlotinib in the treatment of refractory cervical cancer after retrospective analysis of 2 clinical cases.


The clinical records were assessed for the patients who started treatment with erlotinib, on a compassionate-use basis, with an oral dosage of 150mg/day until June 2008. The pharmacy dispensing records were also assessed to evaluate adherence to treatment. Progression-free survival was assessed and adverse reactions were recorded in the medical records.


Three patients with recurrent, advanced cervical cancer were candidates for treatment with erlotinib, 2 of whom were only starting treatment. In both cases, the women had previously received between 3 and 4 different treatment lines. Progression-free survival was 6 months and 4 months in each case. The adverse reactions to the treatment were slight.


Erlotinib presented some similar results to those obtained from cisplatin doublets in women with refractory cervical cancer, with minor adverse effects. However, these results need to be corroborated in the clinical studies field on a wider section of the population.

Carcinoma of the cervix

Evaluar la efectividad y la seguridad del tratamiento con erlotinib en cáncer de cérvix uterino refractario a través del análisis retrospectivo de 2 casos clínicos.


Se revisaron las historias clínicas de las pacientes que iniciaron tratamiento con erlotinib vía oral a dosis de 150mg/día como uso compasivo hasta junio del 2008, así como los registros de dispensación de farmacia para valorar la adherencia al tratamiento. Se evaluó la supervivencia libre de progresión y se recogieron las reacciones adversas descritas en la historia clínica.


Tres pacientes con cáncer de cérvix avanzado recurrente fueron candidatas a tratamiento con erlotinib, 2 de las cuales iniciaron tratamiento. En ambos casos las mujeres habían recibido entre 3 y 4 líneas de tratamiento previas. La supervivencia libre de progresión fue de 6 y 4 meses en cada caso. Las reacciones adversas al tratamiento fueron leves.


El erlotinib presentó unos resultados similares a los logrados con los dobletes de cisplatino en mujeres con cáncer de cérvix refractario, con leves efectos adversos. Sin embargo, habrá que corroborar estos resultados en el ámbito de los ensayos clínicos con poblaciones más amplias.

Palabras clave:
Carcinoma de cérvix
Uso compasivo
Full text is only aviable in PDF
F. Kamanger, G.M. Dores, W.F. Anderson.
Patterns of cancer incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.
J Clin Oncol, 24 (2006), pp. 2137-2150
J.K. Chan, J.S. Berek.
Impact of the human papilloma vaccine on cervical cancer.
J Clin Oncol, 25 (2007), pp. 2975-2982
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer 2008. Available from: http://www.nccn.org
Open database. Search Erlotinib [accesed, Sep 8, 2008]. Available from: http://clinicaltrials.gov
P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, L. Rubinstein, et al.
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
J Natl Cancer Inst, 92 (2000), pp. 205-216
G.A. Omura, J.A. Blessing, L. Vaccarello, M.L. Berman, D.L. Clarke-Pearson, D.G. Mutch, et al.
Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: A Gynecologic Oncology Group study.
J Clin Oncol, 15 (1997), pp. 165-171
D.H. Moore, J.A. Blessing, R.P. McQuellon, H.T. Thaler, D. Cella, J. Benda, et al.
Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
J Clin Oncol, 22 (2004), pp. 3113-3119
H.J. Long 3rd, B.N. Bundy, E.C. Grendys Jr., J.A. Benda, D.S. McMeekin, J. Sorosky, et al.
Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cerviz: a gynecologic oncology group study.
J Clin Oncol, 23 (2005), pp. 4626-4633
A. Goncalves, M. Fabbro, C. Lhommé, L. Gladieff, J.M. Extra, A. Floquet, et al.
A phase II trial to evaluate gefitinib as second- or thirdline treatment in patients with recurring locoregionally advanced or metastatic cervical cancer.
Gynecol Oncol, 108 (2008), pp. 42-46
Copyright © 2009. Sociedad Española de Farmacia Hospitalaria
Article options